Catanzaro Andrew T, Roederer Mario, Koup Richard A, Bailer Robert T, Enama Mary E, Nason Martha C, Martin Julie E, Rucker Steve, Andrews Charla A, Gomez Phillip L, Mascola John R, Nabel Gary J, Graham Barney S
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892-3017, USA.
Vaccine. 2007 May 16;25(20):4085-92. doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7.
Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4(+) [13/14 (93%)] and CD8(+) [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.
一种编码EnvA、EnvB、EnvC以及B亚型Gag、Pol和Nef的六质粒HIV-1 DNA疫苗的无针递送在15名受试者中进行了开放标签评估；14名受试者完成了0、1、2月的疫苗接种计划。通过对CD4(+) [13/14 (93%)] 和CD8(+) [5/14 (36%)] 进行细胞内细胞因子染色，以及在11/14 (79%) 的受试者中通过ELISpot检测到对HIV特异性肽库的T细胞反应。14名受试者中有10名 (71%) 对Env蛋白有ELISA抗体反应。与四质粒产品相比，Gag和Nef特异性T细胞反应有所改善，而Env特异性反应得以维持。这种候选疫苗现已进入II期评估。
